Becton, Dickinson and Company $BDX Shares Acquired by Vontobel Holding Ltd.

Vontobel Holding Ltd. boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 27.5% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 116,608 shares of the medical instruments supplier’s stock after purchasing an additional 25,121 shares during the period. Vontobel Holding Ltd.’s holdings in Becton, Dickinson and Company were worth $20,873,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in BDX. Brown Lisle Cummings Inc. lifted its position in shares of Becton, Dickinson and Company by 9.2% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock valued at $97,000 after buying an additional 54 shares during the last quarter. Pension & Wealth Management Advisors Inc. increased its holdings in Becton, Dickinson and Company by 12.3% in the 3rd quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock worth $94,000 after acquiring an additional 56 shares during the last quarter. Elevation Point Wealth Partners LLC raised its stake in Becton, Dickinson and Company by 3.7% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after acquiring an additional 60 shares during the period. Private Harbour Investment Management & Counsel LLC raised its stake in Becton, Dickinson and Company by 1.1% in the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock valued at $834,000 after acquiring an additional 62 shares during the period. Finally, NorthRock Partners LLC lifted its holdings in Becton, Dickinson and Company by 2.0% during the second quarter. NorthRock Partners LLC now owns 3,295 shares of the medical instruments supplier’s stock valued at $499,000 after purchasing an additional 65 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock traded down $2.42 on Friday, reaching $191.34. The stock had a trading volume of 1,412,670 shares, compared to its average volume of 1,816,545. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $195.99. The company has a market cap of $52.72 billion, a P/E ratio of 57.63, a price-to-earnings-growth ratio of 13.06 and a beta of 0.21. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The business’s 50 day moving average is $184.03 and its two-hundred day moving average is $163.70.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the business earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were given a $1.05 dividend. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Insiders Place Their Bets

In other news, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 6,906 shares of company stock valued at $1,265,855 over the last quarter. 0.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BDX. Jefferies Financial Group reiterated a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Bank of America boosted their price target on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday, August 31st. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Barclays began coverage on shares of Becton, Dickinson and Company in a report on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 price objective for the company. Finally, Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. Seven equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $185.07.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.